(BCPC) Balchem - Ratings and Ratios
Nutrients, Additives, Sterilants, Supplements, Choline
BCPC EPS (Earnings per Share)
BCPC Revenue
Description: BCPC Balchem July 28, 2025
Balchem Corporation is a global developer, manufacturer, and marketer of specialty performance ingredients and products across various industries, including nutrition, food, pharmaceuticals, animal health, and industrial markets. The companys diversified portfolio is organized into three main segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
The Human Nutrition and Health segment is a significant player in the food and beverage industry, offering a range of products such as spray-dried and emulsified powders, extrusion and agglomeration, and blended lipid systems. The segment also provides specialty vitamin K2 and microencapsulation solutions, catering to the growing demand for nutritional and healthy food options. Key performance indicators (KPIs) to watch for this segment include revenue growth, product penetration in the food and beverage industry, and the success of new product launches.
The Animal Nutrition and Health segment provides innovative solutions to enhance animal health and productivity, including microencapsulated products and chelation technology. The segments products are designed to improve nutrient absorption and promote healthy animal growth. KPIs for this segment include sales growth, market share in the animal nutrition market, and the adoption rate of its microencapsulated products.
The Specialty Products segment is a critical supplier of ethylene oxide and ammonia to the healthcare industry, as well as propylene oxide for various industrial applications. The segments products are used in medical device sterilization, fumigation, and crop nutrition. Key metrics to monitor for this segment include revenue growth, the effectiveness of its distribution channels, and the demand for its products in the healthcare and industrial sectors.
From a financial perspective, Balchem Corporations market capitalization stands at approximately $4.9 billion, with a forward P/E ratio of 31.55, indicating a relatively high valuation. The companys return on equity (ROE) is around 11.75%, suggesting a decent level of profitability. To further evaluate the companys performance, additional KPIs such as gross margin ratio, operating cash flow margin, and debt-to-equity ratio should be closely monitored.
BCPC Stock Overview
| Market Cap in USD | 5,078m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1986-06-03 |
BCPC Stock Ratings
| Growth Rating | -1.45% |
| Fundamental | 78.0% |
| Dividend Rating | 48.6% |
| Return 12m vs S&P 500 | -23.7% |
| Analyst Rating | 4.0 of 5 |
BCPC Dividends
| Dividend Yield 12m | 0.56% |
| Yield on Cost 5y | 0.90% |
| Annual Growth 5y | 10.67% |
| Payout Consistency | 98.3% |
| Payout Ratio | 14.3% |
BCPC Growth Ratios
| Growth Correlation 3m | -61.7% |
| Growth Correlation 12m | -69% |
| Growth Correlation 5y | 67.9% |
| CAGR 5y | 4.36% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.19 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.53 |
| Sharpe Ratio 12m | -0.90 |
| Alpha | -24.99 |
| Beta | 0.924 |
| Volatility | 23.01% |
| Current Volume | 162.9k |
| Average Volume 20d | 164.6k |
| Stop Loss | 150.4 (-3.1%) |
| Signal | 0.82 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%) |
| Net Debt (90.7m) to EBITDA (257.7m) ratio: 0.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES) |
| Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 18.60 (EBITDA TTM 257.7m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3) |
Altman Z'' 7.22
| (A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b |
| (B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b |
| (C) 0.12 = EBIT TTM 202.0m / Avg Total Assets 1.63b |
| (D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m |
| Total Rating: 7.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.01
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 3.13% = 1.56 |
| 3. FCF Margin 15.94% = 3.99 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.35 = 2.41 |
| 6. ROIC - WACC (= 2.00)% = 2.50 |
| 7. RoE 12.12% = 1.01 |
| 8. Rev. Trend 85.64% = 6.42 |
| 9. EPS Trend 92.54% = 4.63 |
What is the price of BCPC shares?
Over the past week, the price has changed by -1.11%, over one month by +4.10%, over three months by +2.99% and over the past year by -8.68%.
Is Balchem a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCPC is around 140.78 USD . This means that BCPC is currently overvalued and has a potential downside of -9.26%.
Is BCPC a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BCPC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 200.7 | 29.3% |
| Analysts Target Price | 200.7 | 29.3% |
| ValueRay Target Price | 157.9 | 1.8% |
BCPC Fundamental Data Overview October 25, 2025
P/E Trailing = 34.3816
P/E Forward = 29.2398
P/S = 5.0096
P/B = 3.7439
P/EG = 4.8341
Beta = 0.924
Revenue TTM = 1.01b USD
EBIT TTM = 202.0m USD
EBITDA TTM = 257.7m USD
Long Term Debt = 190.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.17b USD (5.08b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.60 (Ebit TTM 202.0m / Interest Expense TTM 10.9m)
FCF Yield = 3.13% (FCF TTM 161.6m / Enterprise Value 5.17b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.11 (Enterprise Value 5.17b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 156.4m (EBIT 202.0m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 257.7m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.21% (EBIT 202.0m / Capital Employed (Equity 1.23b + L.T.Debt 190.0m))
RoIC = 11.18% (NOPAT 156.4m / Invested Capital 1.40b)
WACC = 9.17% (E(5.08b)/V(5.23b) * Re(9.42%) + D(155.8m)/V(5.23b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 76.33% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 120.6 (DCF Value 3.91b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: 92.54 | EPS CAGR: 14.07% | SUE: 4.0 | # QB: 2
Revenue Correlation: 85.64 | Revenue CAGR: 5.23% | SUE: 1.65 | # QB: 1
Additional Sources for BCPC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle